Karo Healthcare appoints Egil Mølsted Madsen as CFO

We are pleased to announce that Egil Mølsted Madsen will assume the role of CFO at Karo starting on 3…

Karo Group publishes the 2023 Sustainability Report

Today, on 15 April 2024, Karo Group* is publishing its 2023 Sustainability Report on the company’s website, www.karohealthcare.com. For further…

Karo Healthcare expands its presence in Italy with the acquisition of the rights to Proctosedyl® from Bayer

Karo Healthcare AB (‘Karo’) announces the acquisition of the rights to the OTC brand Proctosedyl from Bayer. The transaction transfers…

Karo Healthcare completes the acquisition of the rights to the Global OTC brand Lamisil® from Haleon

Karo Healthcare (‘Karo’) has today completed the previously announced acquisition of the rights to the Global OTC brand Lamisil® from…

Karo Healthcare acquires the Global OTC brand Lamisil® from Haleon

Karo Healthcare (‘Karo’) announces the acquisition of the rights to the Global OTC brand Lamisil® from Haleon UK Holdings Ltd.…

Babak Peyami Joins Karo’s Corporate Management Team as new Head of Digital Commerce

Karo Healthcare announces changes to its Corporate Management Team. Robin List transitions to an advisory role and Babak Peyami is…

Karo Healthcare publishes the 2022 Sustainability Report

Today, on 24 April 2023, Karo Healthcare is publishing its first separate Sustainability Report on the company’s website, www.karohealthcare.com. For…

Financial Report 2022

Michael Kaltenborn appointed CSDO at Karo

Karo Healthcare (“Karo”) has appointed Michael Kaltenborn as Chief Strategy & Corporate Development Officer (CSDO). The appointment of Michael Kaltenborn…

Karo Pharma Aktiebolag’s application for de-listing has been approved

Karo Pharma Aktiebolag’s (“Karo Pharma” or the “Company”) application for de-listing has now been approved by Nasdaq. The last day…

Karo Pharma Aktiebolag applies for de-listing

The Board of Directors of Karo Pharma Aktiebolag (“Karo Pharma” or the “Company”) has resolved to apply for de-listing of…

Karo Intressenter AB initiates compulsory redemption

On 16 August 2022, Karo Intressenter AB[1] (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo Pharma…

Karo Pharma Aktiebolag comments on the public offer from Karo Intressenter AB and obtains a fairness opinion

Background On 16 August 2022, Karo Intressenter AB1 (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo…

Comment from Karo Pharma Aktiebolag’s board of directors regarding the public offer from Karo Intressenter AB

Today, on 16 August 2022, Karo Intressenter AB1 (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo…

Interim report H1 2022

January – June · Revenues amounted to MSEK 1 965.3 (1 460.9), corresponding to an increase of +35% for the…

Karo Pharma enters into an agreement for the potential acquisition of the E45® brand from Reckitt

Karo Pharma Aktiebolag (“Karo”) has today entered into a put option agreement pursuant to which it may acquire the dermatology…

Karo Pharma intends to change listing venue to Nasdaq First North Growth Market during the first half of 2022

The board of directors of Karo Pharma Aktiebolag (publ) (the ”Company” or ”Karo”) has resolved to initiate a process to…

Karo Pharma acquires Sylphar International NV for EUR 290m and intends to carry out a rights issue of approximately EUR 200-250m

Karo Pharma Aktiebolag (publ) (the ”Company” or ”Karo”) has today entered into an agreement to acquire all of the shares…

Karo Pharma Quarterly report Q3 2021

July – September Revenues amounted to MSEK 738.5 (679.1), corresponding to an increase of +9% for the period. The organic…

Anna Hale appointed CMO at Karo Pharma

Karo Pharma Aktiebolag (publ) (“Karo”) has appointed Anna Hale as the Chief Marketing Officer (CMO) of Karo. The appointment reflects Karo’s growth ambitions, fueled by a…

Magnus Nylén leaves Karo Pharma, Matt Roberts appointed new CCO

Karo Pharma Aktiebolag (“Karo”) has appointed Matt Roberts as the new Chief Commercial Officer (CCO) of Karo, replacing Magnus Nylén…

Karo Pharma AB divests its Hospital Supply business, Swereco AB, to J2L Holding AB

As previously announced, Karo Pharma AB (“Karo Pharma”) has carried out a strategic evaluation of the Hospital Supply business unit,…

Karo Pharma publishes third-quarter report 2020 and resolves on sale of own shares

Q3, July – September Net sales amounted to MSEK 679.1 (443.7). This corresponds to an increase of 53% for the…

Second-quarter report 2020

Q2, April – June Net sales amounted to MSEK 688.9 (387.4). This corresponds to an increase of 78% for the…

Annual general meeting 2020 in Karo Pharma Aktiebolag

At today’s annual general meeting of Karo Pharma, the following decisions were passed. The annual general meeting resolved to adopt…

Karo Pharma acquires Pevaryl^® brand portfolio from Cilag GmbH International, an affiliate of Johnson & Johnson

Karo Pharma Aktiebolag (“Karo Pharma”) today announces the signing and closing of the acquisition of the remaining European rights to…

Interim report Q1 2020

January – March Net sales amounted to MSEK 793.6 (420.8). This corresponds to an increase of 89% for the period.…

Karo Pharma acquires product portfolio from LEO Pharma

Karo Pharma acquires a focused intimate care and dermatology product portfolio from the Danish pharmaceutical company LEO Pharma for 90…

Åsa Riisberg leaves the Board of Directors of Karo Pharma at her own request

Åsa Riisberg has notified the Board of Directors of Karo Pharma that she, due to a number of time-consuming commitments,…

Karo Pharma divests Hydrokortison Trimb to Evolan Pharma

As previously communicated, Karo Pharma Aktiebolag (“Karo Pharma”) voluntarily and within a certain time undertook to divest Hydrokortison Trimb and…

Further clarification regarding the ROR-gamma project

On November 5, 2019, Karo Pharma Aktiebolag (“Karo Pharma”) issued a press release regarding the Pfizer collaboration and license agreement…

Interim report January – September 2019

JULY – SEPTEMBER · Net sales amounted to MSEK 443.7 (395.3). This corresponds to an increase of 12% for the…

Termination of project regarding ROR-gamma

In December 2011, Karo Pharma Aktiebolag (”Karo Pharma”) entered into a research collaboration and license agreement with Pfizer, with the…